SCHEMBL4238802

SCHEMBL4238802

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC4CCN(C(=O)CN(C)C)CC4)cc3)cc2)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.42
TTK P33981 1/20 0.42
PKM P14618 1/20 0.42
MCHR1 Q99705 4/20 0.42
ALDH1A1 P00352 3/20 0.41
TP53 P04637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.41
HRH3 Q9Y5N1 1/20 0.41
KMT2A Q03164 2/20 0.40
NAMPT P43490 2/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FGFR1 P11362 1/20 0.39
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4229212 0.89 MCHR1 (0.51) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL4238227 0.89 MCHR1 (0.46) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL4231912 0.88 PKM (0.45) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL4233292 0.88 HRH3 (0.48) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL4236845 0.88 HRH3 (0.48) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL4226921 0.88 MCHR1 (0.45) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL4235333 0.87 SMN1; SMN2 (0.52) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL13699303 0.87 PKM (0.45) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL4238167 0.86 MCHR1 (0.52) PKMMCHR1ALDH1A1TP53NPC1
SCHEMBL4232443 0.86 FGFR1 (0.49) PKMMCHR1ALDH1A1TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R CYP3A4 2140/4885TTK 1689/4885PKM 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.